🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC

RecruitingPhase 3Ages 18 Years - 90 YearsAllSahlgrenska University Hospital
NCT06714604 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this multicenter randomized controlled phase III trial is to compare two durations of neoadjuvant chemotherapy (NAT) with mFOLFIRINOX or gemcitabine-nab-paclitaxel (GnP) before attempt for surgical resection in patients with borderline (BR) and locally advanced pancreatic cancer (LAPC). Patients with histologically confirmed non-metastatic BR/LAPC evaluated to potentially tolerate any of the treatment regimens and pancreatic surgery will be randomized to receive either standard duration NAT with 6 cycles mFOLFIRINOX or 4 cycles GnP or prolonged duration NAT with either 12 cycles mFOLFIRINOX or 6 cycles GnP before attempt for surgical resection, provided there is no evidence of disease progression. The primary objective is to compare the overall survival at 24 months after randomization of all treated patients and among the resected patients with BR/LAPC.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Borderline or locally advanced pancreatic adenocarcinoma at diagnosis according to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines, version 1.2022 * Histo- or cytologically confirmed adenocarcinoma (preferably EUS-guided) * T1-4, Nx, M0 according to AJCC 8th edition * ECOG 0-1 and considered fit for the planned chemotherapy at the local hospital and surgery at the two national centers for BR/LAPC * Written informed patient consent Exclusion Criteria: * Co-morbidity precluding pancreatic surgery or chemotherapy * Contraindications to any of the drugs in the proposed treatment regimens * ECOG ≥2 * Neuropathy ≥ grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE), version 6 * Granulocyte count \< 1500 per cubic millimetre (\< 1,5 x 109/L) * Platelet count \< 100 000 per cubic millimetre (\< 100 x 109/L) * Serum creatinine \> 1.5 UNL (upper limit normal range) * Albumin \<2,5 g/dl (\<25 g/L) * Total bilirubin \>3 x ULN * ASAT (SGOT) and ALAT (SGPT) \>2.5 x institutional ULN * female patients in child-bearing age not using adequate contraception, pregnant or lactating women * mental or somatic disorders which could possibly interfere with informed consent, compliance or the planned treatments * previous oncologic treatment for PC within the past 5 years * participation in other clinical trial with an investigational product during the past 30 days * Any reason according to the investigator why the patient cannot comply with the protocol or is not suitable to participate
💊

What it tests

  • FOLFIRINOX or gemcitabine-nab-paclitaxel
  • FOLFIRINOX or gemcitabine-nab-paclitaxel
📍

Where

1 site
SahlgrenskaUH
Gothenburg, Sweden
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy